Research programme: antibacterials - ImaGene

Drug Profile

Research programme: antibacterials - ImaGene

Alternative Names: OX-22-043; OX-22-045; Oxazolidinone antibacterials research programme - ImaGene; PDF 10034; PDF 10035; Peptide deformylase inhibitors research programme - ImaGene

Latest Information Update: 01 May 2007

Price : $50

At a glance

  • Originator ImaGene
  • Class
  • Mechanism of Action Peptide deformylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Gram-positive infections

Most Recent Events

  • 27 Nov 2002 Preclinical trials in Gram-positive infections in South Korea (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top